NASDAQ:GMDAGamida Cell Stock Price, Forecast & News

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GMDA shares have increased by 4.3% and is now trading at $4.41. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gamida Cell.

Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gamida Cell.

Gamida Cell Ltd (NASDAQ:GMDA) released its earnings results on Thursday, May, 21st. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.12. View Gamida Cell's earnings history.

7 Wall Street analysts have issued 12-month price targets for Gamida Cell's shares. Their forecasts range from $13.00 to $20.00. On average, they expect Gamida Cell's share price to reach $16.33 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View analysts' price targets for Gamida Cell.

Media headlines about GMDA stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Gamida Cell earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Gamida Cell.

Some companies that are related to Gamida Cell include Harpoon Therapeutics (HARP), Tcr2 Therapeutics (TCRR), Brainstorm Cell Therapeutics (BCLI), PDL BioPharma (PDLI), Cellular Biomedicine Group (CBMG), BIONDVAX PHARMA/S (BVXV), Cabaletta Bio (CABA), Dyadic International (DYAI), ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI), Gritstone Oncology (GRTS), Eiger Biopharmaceuticals (EIGR), Pluristem Therapeutics (PSTI), Jounce Therapeutics (JNCE) and Fennec Pharmaceuticals (FENC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Outlook Therapeutics (OTLK), PhaseBio Pharmaceuticals (PHAS), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX) and Cyclacel Pharmaceuticals (CYCC).

(GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GMDA stock can currently be purchased for approximately $4.41.

Gamida Cell has a market capitalization of $106.81 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Gamida Cell employs 79 workers across the globe.

The official website for Gamida Cell is www.gamida-cell.com.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]